Podstawowe statystyki
| LEI | Z6C0YCECH9DCU5ZIQW84 |
| CIK | 816956 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to CONMED Corporation
SEC Filings (Chronological Order)
Na tej stronie znajduje się pełna, chronologiczna lista zgłoszeń SEC, z wyłączeniem zgłoszeń własności, które udostępniamy gdzie indziej.
| June 4, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 3, 2026 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of incorporation or organization) (C |
|
| June 4, 2026 |
PURCHASE AGREEMENT June 3, 2026 PURCHASE AGREEMENT June 3, 2026 [●] (the “Undersigned”), for itself and on behalf of the beneficial owners listed on Exhibit A hereto (the “Accounts”) for whom the Undersigned holds contractual and investment authority (each Account, as well as the Undersigned if it is selling Outstanding Notes (as defined below), referred to hereunder as a “Holder”), enters into this Purchase Agreement (this “Agreement”) with CONMED Corporation, a Delaware corporation (the “Company”), as of the date first written above, pursuant to which the Company will purchase from each Holder the Outstanding Notes held by each Holder and specified on Exhibit A hereto for an amount in cash equal to the Cash Consideration (as defined in Exhibit A hereto). |
|
| June 1, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 27, 2026 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of incorporation or organization) (C |
|
| June 1, 2026 |
FIRST OMNIBUS AMENDMENT AND INCREASED FACILITY ACTIVATION NOTICE Exhibit 10.1 Execution Version FIRST OMNIBUS AMENDMENT AND INCREASED FACILITY ACTIVATION NOTICE FIRST AMENDMENT AND INCREASED FACILITY ACTIVATION NOTICE, dated as of May 27, 2026 (this “Amendment”), to (a) the Eighth Amended and Restated Credit Agreement, dated as of June 10, 2025 (as amended, amended and restated or otherwise modified from time to time prior to the date hereof, the “Credit Agreem |
|
| May 28, 2026 |
CONMED Corporation Conflict Minerals Report For the Year Ended December 31, 2025 Exhibit 1.01 CONMED Corporation Conflict Minerals Report For the Year Ended December 31, 2025 We have made statements in this Conflict Minerals Report that may constitute forward-looking statements about our plans to take additional actions or to implement additional procedures with respect to our due diligence efforts to determine the origin of conflict minerals included in our products. There ca |
|
| May 28, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of (Commission (I.R.S. Employer incorporation or organization) File Number) Identification No.) 11311 Concept Blvd. Largo FL 33773-4908 (Address of principal |
|
| May 20, 2026 |
CONMED Corporation Appoints Celine Martin and Jeff Mirviss to its Board of Directors NEWS RELEASE CONTACT: CONMED Corporation Dalton Henry Investor Relations Analyst IR@conmed. |
|
| May 20, 2026 |
AMENDED AND RESTATED BY-LAWS OF CONMED CORPORATION Effective May 19, 2026 ARTICLE I Stockholders AMENDED AND RESTATED BY-LAWS OF CONMED CORPORATION Effective May 19, 2026 ARTICLE I Stockholders Section 1. |
|
| May 20, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 18, 2026 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of incorporation or organization) (C |
|
| May 20, 2026 |
CONMED CORPORATION AMENDED AND RESTATED 2025 LONG-TERM INCENTIVE PLAN NON-EMPLOYEE DIRECTOR RESTRICTED STOCK UNIT AGREEMENT AGREEMENT, dated as of the Grant Date set forth on Schedule I, between CONMED Corporation (the “Company”) and the Non-Employee Director (“Director”) of the Company elected at the 2025 Annual Shareholder Meeting, and as listed on Schedule I. |
|
| April 30, 2026 |
APPENDIX A RESTRICTIVE COVENANT AGREEMENT Exhibit 10.1 Stock Option Award Terms O V E R V I E W Our Stock Options rewards program is generally designed to encourage long-term service and performance that creates value for our shareholders. This overview of the program does not amend or qualify any of the Award Terms, but is provided for a convenient summary of certain key terms. In the event of a conflict between this overview and the ter |
|
| April 30, 2026 |
APPENDIX A RESTRICTIVE COVENANT AGREEMENT Exhibit 10.2 Restricted Stock Unit Award Terms O V E R V I E W Our Restricted Stock Units (“RSUs”) rewards program is generally designed to encourage long-term service and performance that creates value for our shareholders. This overview of the program does not amend or qualify any of the Award Terms, but is provided for a convenient summary of certain key terms. In the event of a conflict betwee |
|
| April 30, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended Commission File Number March 31, 2026 001-39218 CONMED CORPORATION (Exact name of the registrant as spe |
|
| April 30, 2026 |
CONMED CORPORATION 2025 LONG-TERM INCENTIVE PLAN PERFORMANCE SHARE UNIT AGREEMENT Exhibit 10.3 CONMED CORPORATION 2025 LONG-TERM INCENTIVE PLAN PERFORMANCE SHARE UNIT AGREEMENT AGREEMENT, dated as of the Grant Date set forth on Schedule I, between CONMED Corporation (the “Company”) and the Non-Employee Director (“Director”) of the Company elected at the 2025 Annual Shareholder Meeting, and as listed on Schedule I. Capitalized terms not defined herein shall have the meanings asc |
|
| April 29, 2026 |
CONMED Corporation Announces First Quarter 2026 Financial Results NEWS RELEASE CONTACT: CONMED Corporation Dalton Henry Investor Relations Analyst ir@conmed. |
|
| April 29, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 29, 2026 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of incorporation or organization) |
|
| April 7, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant þ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) þ Definitive Proxy State |
|
| April 7, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| April 7, 2026 |
2026Dear Fellow CONMED Stockholder, On behalf of the Board of Directors and the management team, thank you for your investment in CONMED. |
|
| March 13, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 13, 2026 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of incorporation or organization) |
|
| February 17, 2026 |
United States Securities and Exchange Commission Washington, D.C. 20549 Form 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended: December 31, 2025 Commission file number: 001-39218 CONMED CORPORATION (Exact name of registrant as specified |
|
| February 17, 2026 |
EXHIBIT 19 Insider Trading Policy 1.Policy Statement This Insider Trading Policy (this “Policy”) is designed to prevent insider trading or allegations of insider trading, to protect the reputation of CONMED, its subsidiaries, and affiliated entities (collectively, the “Company”) for integrity and ethical conduct and to help the Company’s personnel avoid the severe consequences associated with viol |
|
| February 17, 2026 |
APPENDIX A RESTRICTIVE COVENANT AGREEMENT Exhibit 10.37 Restricted Stock Unit Award Terms O V E R V I E W Our Restricted Stock Units (“RSUs”) rewards program is generally designed to encourage long term service and performance that creates value for our shareholders. This overview of the program does not amend or qualify any of the Award Terms, but is provided for a convenient summary of certain key terms. Vesting RSUs vest over a four (4 |
|
| February 17, 2026 |
PERFORMANCE SHARE UNIT AGREEMENT Exhibit 10.38 PERFORMANCE SHARE UNIT AGREEMENT AGREEMENT (this “Agreement”), dated as of March 3, 2025, between CONMED Corporation (the “Company”) and the employee of the Company named on Schedule I (the “Employee”). Capitalized terms not defined herein shall have the meanings ascribed to them in the Company’s 2018 Long- Term Incentive Plan (the “Plan”). The parties hereto agree as follows: 1.Gran |
|
| February 17, 2026 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM EXHIBIT 23 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. |
|
| February 17, 2026 |
CONMED Corporation Subsidiaries of the Registrant EXHIBIT 21 CONMED Corporation Subsidiaries of the Registrant Name State or Country of Incorporation Aspen Laboratories, Inc. |
|
| February 17, 2026 |
Exhibit 4.1 Description of Common Stock The following is a description of the general terms, provisions and rights of the common stock, par value $0.01 ("Common Stock"), of CONMED Corporation, a Delaware corporation (the "Company," "we," "us," and "our"), related provisions of the Company’s certificate of incorporation (the “Certificate of Incorporation”) and bylaws (the “Bylaws”) and applicable D |
|
| February 17, 2026 |
RESTRICTIVE COVENANT AGREEMENT EXHIBIT 10.36 Stock Option Award Terms O V E R V I E W Our Stock Options rewards program is generally designed to encourage long term service and performance that creates value for our shareholders. This overview of the program does not amend or qualify any of the Award Terms, but is provided for a convenient summary of certain key terms. Exercise Price The exercise price is the closing price of C |
|
| January 28, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 28, 2026 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of incorporation or organization |
|
| January 28, 2026 |
CONMED Corporation Announces Fourth Quarter and Full-Year 2025 Financial Results NEWS RELEASE CONTACT: CONMED Corporation Pat Beyer Chief Executive Officer PatBeyer@conmed. |
|
| January 12, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 12, 2026 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of incorporation or organization |
|
| January 12, 2026 |
J.P. Morgan 44 th Annual Healthcare Conference Pat J. Beyer President and Chief Executive Officer Todd W. Garner Executive Vice President and Chief Financial Officer January 12 th , 2026 Forward - Looking Information This presentation may contain forward - looking statements based on certain assumptions and contingencies that involve risks and uncertainties, which could cause actual results, perfo |
|
| January 8, 2026 |
John Ferrell EVP, Chief Human Resource Officer 11311 Concept Blvd Largo, FL 33773 January 6, 2026 Todd W. |
|
| January 8, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 6, 2026 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of incorporation or organization) |
|
| December 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 5, 2025 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of incorporation or organization |
|
| December 5, 2025 |
Exhibit 99.1 NEWS RELEASE CONTACT: CONMED Corporation Todd W. Garner Chief Financial Officer [email protected] CONMED Corporation Announces Strategic Exit from Gastroenterology Product Lines Concludes Distribution Agreement with Gore® for VIABIL® in the United States and Canada, Effective January 1, 2026 Announces Intent to Exit Remaining Products in its Gastroenterology Product Portfolio Reaf |
|
| November 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended Commission File Number September 30, 2025 001-39218 CONMED CORPORATION (Exact name of the registrant as |
|
| November 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 5, 2025 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of incorporation or organization |
|
| November 5, 2025 |
CONMED Corporation Announces Third Quarter 2025 Financial Results NEWS RELEASE CONTACT: CONMED Corporation Todd W. Garner Chief Financial Officer [email protected] CONMED Corporation Announces Third Quarter 2025 Financial Results Largo, Florida, November 5, 2025 – CONMED Corporation (NYSE: CNMD) today announced financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Highlights •Sales of $337.9 million increased 6.7% year-over-yea |
|
| September 12, 2025 |
144 0001615538 XXXXXXXX LIVE 0000816956 CONMED Corp 001-39218 11311 CONCEPT BOULEVARD LARGO FL 33773 727-214-2974 Farkas Charles Director Common Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917 2000 107049. |
|
| September 9, 2025 |
CONMED Corporation Adds Kim Kelderman to its Board of Directors NEWS RELEASE CONTACT: CONMED Corporation Todd Garner Chief Financial Officer ToddGarner@conmed. |
|
| September 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 8, 2025 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of (Commission File Number) (I. |
|
| August 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 7, 2025 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of incorporation or organization) |
|
| July 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended Commission File Number June 30, 2025 001-39218 CONMED CORPORATION (Exact name of the registrant as spec |
|
| July 30, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 30, 2025 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of incorporation or organization) ( |
|
| July 30, 2025 |
CONMED Corporation Announces Second Quarter 2025 Financial Results NEWS RELEASE CONTACT: CONMED Corporation Todd W. Garner Chief Financial Officer [email protected] CONMED Corporation Announces Second Quarter 2025 Financial Results Largo, Florida, July 30, 2025 – CONMED Corporation (NYSE: CNMD) today announced financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Highlights •Sales of $342.3 million increased 3.1% year-over-year as |
|
| July 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 7, 2025 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of incorporation or organization) (C |
|
| July 7, 2025 |
Exhibit 99.1 NEWS RELEASE CONTACT: CONMED Corporation Todd Garner Chief Financial Officer [email protected] Martha Aronson to Step Down from CONMED Board of Directors Following Appointment as President and Chief Executive Officer of Merit Medical Systems, Inc. Largo, Fla. – July 7, 2025 – CONMED Corporation (NYSE: CNMD) today announced that Martha Aronson will be stepping down from the company |
|
| June 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 11-K ý Annual Report Pursuant To Section 15(d) Of The Securities Exchange Act of 1934 For the fiscal year ended December 31, 2024 OR ¨ Transition Report Pursuant To Section 15(d) Of The Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-39218 (A) Full title of the plan and the add |
|
| June 16, 2025 |
Exhibit 10.1 EIGHTH AMENDED AND RESTATED CREDIT AGREEMENT among CONMED CORPORATION, as Parent Borrower, The Foreign Subsidiary Borrowers From Time to Time Party Hereto, The Several Lenders from Time to Time Party Hereto, and JPMORGAN CHASE BANK, N.A., as Administrative Agent Dated as of June 10, 2025 JPMORGAN CHASE BANK, N.A., BOFA SECURITIES INC., and WELLS FARGO SECURITIES, LLC, as Joint Lead Ar |
|
| June 16, 2025 |
Exhibit 10.2 AMENDED AND RESTATED GUARANTEE AND COLLATERAL AGREEMENT made by CONMED CORPORATION and certain of its Subsidiaries in favor of JPMORGAN CHASE BANK, N.A., as Administrative Agent Dated as of June 10, 2025 Table of Contents Page Section 1. DEFINED TERMS 1 1.1 Definitions 2 1.2 Other Definitional Provisions 5 Section 2. Guarantee 5 2.1 Guarantee 5 2.2 Right of Contribution 6 2.3 No Subro |
|
| June 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2025 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of incorporation) (Commission File N |
|
| May 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of (Commission (I.R.S. Employer incorporation or organization) File Number) Identification No.) 11311 Concept Blvd. Largo FL 33773-4908 (Address of principal |
|
| May 29, 2025 |
Conflict Minerals Report as responsive to Item 1.01 and 1.02 of this Form. Exhibit 1.01 CONMED Corporation Conflict Minerals Report For the Year Ended December 31, 2024 We have made statements in this Conflict Minerals Report that may constitute forward-looking statements about our plans to take additional actions or to implement additional procedures with respect to our due diligence efforts to determine the origin of conflict minerals included in our products. There ca |
|
| May 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 19, 2025 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of (Commission File Number) (I.R.S. |
|
| May 20, 2025 |
Calculation of Filing Fee Tables S-8 CONMED Corp Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Stock, par value $0. |
|
| May 20, 2025 |
As filed with the Securities and Exchange Commission on May 20, 2025. S-8 POS As filed with the Securities and Exchange Commission on May 20, 2025. Registration No. 333-214299 Registration No. 333-228171 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 2 to Form S-8 Registration Statement No. 333-214299 Post-Effective Amendment No. 2 to Form S-8 Registration Statement No. 333-228171 Under the Securities Act of 1933 |
|
| May 20, 2025 |
CONMED Corporation 2025 Long-Term Incentive Plan.* EXHIBIT 4.3 CONMED CORPORATION 2025 LONG-TERM INCENTIVE PLAN 1. PURPOSE. The purpose of the 2025 Long-Term Incentive Plan of CONMED Corporation (as amended from time to time, the “Plan”) is to promote the long-term financial interests of CONMED Corporation (the “Company”), including its growth and performance, by encouraging employees of the Company and its subsidiaries and Non-Employee Directors |
|
| May 20, 2025 |
As filed with the Securities and Exchange Commission on May 20, 2025. S-8 POS As filed with the Securities and Exchange Commission on May 20, 2025. Registration No. 333-214299 Registration No. 333-228171 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 2 to Form S-8 Registration Statement No. 333-214299 Post-Effective Amendment No. 2 to Form S-8 Registration Statement No. 333-228171 Under the Securities Act of 1933 |
|
| May 20, 2025 |
As filed with the Securities and Exchange Commission on May 20, 2025 As filed with the Securities and Exchange Commission on May 20, 2025 Registration No. |
|
| May 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| May 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended Commission File Number March 31, 2025 001-39218 CONMED CORPORATION (Exact name of the registrant as spe |
|
| April 30, 2025 |
CONMED Corporation Announces First Quarter 2025 Financial Results NEWS RELEASE CONTACT: CONMED Corporation Todd W. Garner Chief Financial Officer 727-214-2975 [email protected] CONMED Corporation Announces First Quarter 2025 Financial Results Largo, Florida, April 30, 2025 – CONMED Corporation (NYSE: CNMD) today announced financial results for the first quarter ended March 31, 2025. First Quarter 2025 Highlights · Sales of $321.3 million increased 2.9% year- |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 30, 2025 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of (Commission File Number) (I.R.S |
|
| April 8, 2025 |
DEFA14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 8, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi |
|
| April 8, 2025 |
ANNUAL REPORT -~tt ,.........c ~CONMED ~CONMED ZOZ¥ Annual Repor1 Contents Introduction 4 Company Financial Snapshot 5 Letter to Stockholders 6 Featured Spotlights 10 Board of Directors & Executive Leadership Team 18 Additional Information 20 GAAP to Non-GAAP Reconciliations 22 CONMED 10-K 24 ~CONMED 4 I lnlroduc•1on Foundations of the Future At CONMED, we believe that strong foundations drive las |
|
| April 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 1, 2025 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of (Commission File Number) (I.R.S. |
|
| February 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 24, 2025 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of (Commission File Number) (I. |
|
| February 25, 2025 |
CONMED Corporation Adds Mark Kaye to its Board of Directors NEWS RELEASE CONTACT: CONMED Corporation Todd W. Garner Chief Financial Officer 727-214-2975 [email protected] CONMED Corporation Adds Mark Kaye to its Board of Directors Largo, Fla. - February 25, 2025 – CONMED Corporation (NYSE: CNMD) today announced that Mark Kaye will be joining its Board of Directors effective February 24th, 2025. “My fellow directors and I are extremely pleased to welcom |
|
| February 18, 2025 |
United States Securities and Exchange Commission Washington, D.C. 20549 Form 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended: December 31, 2024 Commission file number: 001-39218 CONMED CORPORATION (Exact name of registrant as specified |
|
| February 18, 2025 |
Description of the Common Stock of CONMED Corporation, a Delaware corporation. Exhibit 4.1 Description of Common Stock The following is a description of the general terms, provisions and rights of the common stock, par value $0.01 ("Common Stock"), of CONMED Corporation, a Delaware corporation (the "Company," "we," "us," and "our"), related provisions of the Company’s certificate of incorporation (the “Certificate of Incorporation”) and bylaws (the “Bylaws”) and applicable D |
|
| February 18, 2025 |
Subsidiaries of the Registrant. EXHIBIT 21 CONMED Corporation Subsidiaries of the Registrant Name State or Country of Incorporation Aspen Laboratories, Inc. |
|
| February 18, 2025 |
EXHIBIT 19 Insider Trading Policy 1.Policy Statement This Insider Trading Policy (this “Policy”) is designed to prevent insider trading or allegations of insider trading, to protect the reputation of CONMED, its subsidiaries, and affiliated entities (collectively, the “Company”) for integrity and ethical conduct and to help the Company’s personnel avoid the severe consequences associated with viol |
|
| February 5, 2025 |
CONMED Corporation Announces Fourth Quarter and Full-Year 2024 Financial Results NEWS RELEASE CONTACT: CONMED Corporation Todd W. Garner Chief Financial Officer 727-214-2975 [email protected] CONMED Corporation Announces Fourth Quarter and Full-Year 2024 Financial Results Largo, Fla. - February 5, 2025 – CONMED Corporation (NYSE: CNMD) today announced financial results for the fourth quarter and full-year ended December 31, 2024. Fourth Quarter 2024 Highlights · Sales of $ |
|
| February 5, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 5, 2025 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of (Commission File Number) (I.R |
|
| January 13, 2025 |
J.P. Morgan 43rd Annual Healthcare Conference Exhibit 99.1 J.P. Morgan 43rd Annual Healthcare Conference Forward-Looking Information This presentation may contain forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties, which could cause actual results, performance, or trends to differ materially from those expressed in the forward-looking statements herein or in previous disclosures. For |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 13, 2025 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of incorporation or organization |
|
| December 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 9, 2024 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of (Commission File Number) (I.R |
|
| November 13, 2024 |
SC 13G/A 1 cnmd13g6th0924.txt CONMED CORPORATION - 09/30/2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.6) CONMED CORPORATION - (Name of Issuer) Common Stock - (Title of Class of Securities) 207410101 - (CUSIP Number) 09/30/2024 - (Date of Event Which Requires Filing of this Statement) Check the appr |
|
| November 12, 2024 |
CNMD / CONMED Corporation / Capital Research Global Investors - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* CONMED Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 207410101 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desig |
|
| October 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended Commission File Number September 30, 2024 001-39218 CONMED CORPORATION (Exact name of the registrant as |
|
| October 30, 2024 |
Exhibit 10.1 DATED October 30, 2024 BETWEEN CONMED U.K. LIMITED (1) PAT BEYER (2) SERVICE AGREEMENT CONTENTS 1. DEFINITIONS AND INTERPRETATION 1 2. TERM OF EMPLOYMENT 3 3. JOB TITLE AND DUTIES 3 4. EMPLOYEE WARRANTIES 5 5. PLACE OF WORK 6 6. REMUNERATION AND BENEFITS 6 7. EXPENSES 9 8. NORMAL HOURS OF WORK 10 9. HOLIDAY ENTITLEMENT 10 10. NOTIFICATION OF SICKNESS OR OTHER ABSENCE AND MEDICAL EXAMI |
|
| October 30, 2024 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2024 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of incorporation) (Commission Fil |
|
| October 30, 2024 |
Letter Agreement, by and between CONMED and Curt R. Hartman, dated October 30, 2024. Exhibit 10.2 Martha Goldberg Aronson 11311 Concept Blvd Largo, FL 33773 October 30, 2024 Curt R. Hartman Address on file with the Company Re: Transition to Special Advisor Dear Curt: This letter (this “Letter Agreement”) confirms our recent discussions regarding your transition to a Special Advisor role with CONMED Corporation (the “Company”). On behalf of the Board of Directors of the Company (th |
|
| October 30, 2024 |
CONMED Corporation Announces Third Quarter 2024 Financial Results Exhibit 99.1 NEWS RELEASE CONTACT: CONMED Corporation Todd W. Garner Chief Financial Officer 727-214-2975 [email protected] CONMED Corporation Announces Third Quarter 2024 Financial Results Largo, Florida, October 30, 2024 – CONMED Corporation (NYSE: CNMD) today announced financial results for the third quarter ended September 30, 2024. Third Quarter 2024 Highlights • Sales of $316.7 millio |
|
| October 4, 2024 |
CONMED Corporation Announces Preliminary Third Quarter Financial Information EX-99.1 Exhibit 99.1 NEWS RELEASE CONTACT: CONMED Corporation Todd W. Garner Chief Financial Officer 727-214-2975 [email protected] CONMED Corporation Announces Preliminary Third Quarter Financial Information LARGO, Fla. – October 4, 2024 –As a follow up to the Current Report on Form 8-K issued by the Company on September 30, 2024, CONMED Corporation (NYSE: CNMD) announced preliminary financia |
|
| October 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 4, 2024 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of incorporation or organization) |
|
| September 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 30, 2024 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of incorporation or organizati |
|
| September 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 16, 2024 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of incorporation or organizati |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2024 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of incorporation) (Commission File |
|
| August 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 9, 2024 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of (Commission File Number) (I.R.S |
|
| August 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended Commission File Number June 30, 2024 001-39218 CONMED CORPORATION (Exact name of the registrant as spec |
|
| August 1, 2024 |
Exhibit 10.1 FOURTH AMENDMENT FOURTH AMENDMENT, dated as of July 19, 2024 (this “Amendment”), to the Seventh Amended and Restated Credit Agreement, dated as of July 16, 2021 (as amended, supplemented or otherwise modified from time to time, the “Credit Agreement”), among CONMED Corporation, a Delaware corporation (the “Parent Borrower”), the Foreign Subsidiary Borrowers (as defined therein) from t |
|
| July 31, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 31, 2024 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of (Commission File Number) (I.R.S. |
|
| July 31, 2024 |
CONMED Corporation Announces Second Quarter 2024 Financial Results NEWS RELEASE CONTACT: CONMED Corporation Todd W. Garner Chief Financial Officer 727-214-2975 [email protected] CONMED Corporation Announces Second Quarter 2024 Financial Results Largo, Florida, July 31, 2024 – CONMED Corporation (NYSE: CNMD) today announced financial results for the second quarter ended June 30, 2024. Second Quarter 2024 Highlights · Sales of $332.1 million increased 4.5% year |
|
| June 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 11-K ý Annual Report Pursuant To Section 15(d) Of The Securities Exchange Act of 1934 For the fiscal year ended December 31, 2023 OR ¨ Transition Report Pursuant To Section 15(d) Of The Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-39218 (A) Full title of the plan and the add |
|
| May 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 22, 2024 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of (Commission File Number) (I.R.S. |
|
| May 22, 2024 |
Other Events, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 22, 2024 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of incorporation or organization) (C |
|
| May 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of (Commission (I.R.S. Employer incorporation or organization) File Number) Identification No.) 11311 Concept Blvd. Largo FL 33773-4908 (Address of principal |
|
| May 21, 2024 |
Conflict Minerals Report as responsive to Item 1.01 and 1.02 of this Form. Exhibit 1.01 CONMED Corporation Conflict Minerals Report For the Year Ended December 31, 2023 We have made statements in this Conflict Minerals Report that may constitute forward-looking statements about our plans to take additional actions or to implement additional procedures with respect to our due diligence efforts to determine the origin of conflict minerals included in our products. There ca |
|
| April 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended Commission File Number March 31, 2024 001-39218 CONMED CORPORATION (Exact name of the registrant as spe |
|
| April 24, 2024 |
Exhibit 10.1 CONFIDENTIAL April 24, 2024 Mr. Pat Beyer 11 River Park Drive Marlow, Buckinghamshire, England SL7 1QT Re: Amended Employment Terms Dear Pat: Please accept this letter as Amendment Number 1 (this “Amendment”) to your April 25, 2019, Service Agreement with CONMED U.K. Limited (the “Service Agreement”). This Amendment will supplement and amend your Service Agreement effective as of Apri |
|
| April 24, 2024 |
CONMED Corporation Announces First Quarter 2024 Financial Results NEWS RELEASE CONTACT: CONMED Corporation Todd W. Garner Chief Financial Officer 727-214-2975 [email protected] CONMED Corporation Announces First Quarter 2024 Financial Results Largo, Florida, April 24, 2024 – CONMED Corporation (NYSE: CNMD) today announced financial results for the first quarter ended March 31, 2024. First Quarter 2024 Highlights · Sales of $312.3 million increased 5.7% year- |
|
| April 24, 2024 |
Letter Agreement, by and between CONMED and Heather Cohen, dated April 19, 2024 Exhibit 10.2 CONFIDENTIAL Curt R. Hartman 11311 Concept Blvd Largo, FL 33773 April 19, 2024 Heather L. Cohen Address on file with the Company Re: Transition to Special Advisor Dear Heather: This letter (this “Letter Agreement”) confirms our recent discussions regarding your transition to a Special Advisor role with CONMED Corporation (the “Company”). On behalf of the Board of Directors of the Comp |
|
| April 24, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 24, 2024 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of (Commission File Number) (I.R.S |
|
| April 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 19, 2024 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of incorporation) (Commission File |
|
| April 8, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi |
|
| April 8, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi |
|
| April 8, 2024 |
ANNUAL REPORT 2023Introduction Company Financial Snapshot Letter to Shareholders Featured Spotlights Board Members, Executive Team & Other Business Leaders Additional Information GAAP to Non-GAAP Reconciliations CONMED 10-K 4 5 6 8 16 18 20 22 2023 ANNUAL REPORT Contents4 | Introduction In an ever-evolving healthcare landscape, CONMED remains committed to innovating and striving for excellence in everything we do. |
|
| February 28, 2024 |
United States Securities and Exchange Commission Washington, D.C. 20549 Form 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended: December 31, 2023 Commission file number: 001-39218 CONMED CORPORATION (Exact name of registrant as specified |
|
| February 28, 2024 |
Subsidiaries of the Registrant. EXHIBIT 21 CONMED Corporation Subsidiaries of the Registrant Name State or Country of Incorporation Aspen Laboratories, Inc. |
|
| February 28, 2024 |
Exhibit 97 CONMED CORPORATION POLICY FOR THE RECOVERY OF ERRONEOUSLY AWARDED INCENTIVE-BASED COMPENSATION I. |
|
| February 28, 2024 |
Description of the Common Stock of CONMED Corporation, a Delaware corporation. Exhibit 4.1 Description of Common Stock The following is a description of the general terms, provisions and rights of the common stock, par value $0.01 ("Common Stock"), of CONMED Corporation, a Delaware corporation (the "Company," "we," "us," and "our"), related provisions of the Company’s certificate of incorporation (the “Certificate of Incorporation”) and bylaws (the “Bylaws”) and applicable D |
|
| February 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 26, 2024 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of (Commission File Number) (I. |
|
| February 13, 2024 |
CNMD / CONMED Corporation / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0669-conmedcorp.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 13)* Name of issuer: CONMED Corp Title of Class of Securities: Common Stock CUSIP Number: 207410101 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pu |
|
| February 12, 2024 |
SC 13G/A 1 cnmd13g5th1223.txt CONMED CORPORATION - 12/31/2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.5) CONMED CORPORATION - (Name of Issuer) Common Stock - (Title of Class of Securities) 207410101 - (CUSIP Number) 12/31/2023 - (Date of Event Which Requires Filing of this Statement) Check the appr |
|
| February 9, 2024 |
CNMD / CONMED Corporation / Capital Research Global Investors - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* CONMED Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 207410101 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design |
|
| January 31, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 31, 2024 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of (Commission File Number) (I.R |
|
| January 31, 2024 |
CONMED Corporation Announces Fourth Quarter and Full-Year 2023 Financial Results NEWS RELEASE CONTACT: CONMED Corporation Todd W. Garner Chief Financial Officer 727-214-2975 [email protected] CONMED Corporation Announces Fourth Quarter and Full-Year 2023 Financial Results Largo, Florida, January 31, 2024 – CONMED Corporation (NYSE: CNMD) today announced financial results for the fourth quarter and full-year ended December 31, 2023. Fourth Quarter 2023 Highlights · Sales of |
|
| January 22, 2024 |
CNMD / CONMED Corporation / BlackRock Inc. Passive Investment SC 13G/A 1 us2074101013012224.txt us2074101013012224.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 19) CONMED CORPORATION - (Name of Issuer) Common Stock - (Title of Class of Securities) 207410101 - (CUSIP Number) December 31, 2023 - (Date of Event Which Requires Filing of this Statement) Check the appropriate bo |
|
| December 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 4, 2023 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of (Commission File Number) (I.R |
|
| October 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended Commission File Number September 30, 2023 001-39218 CONMED CORPORATION (Exact name of the registrant as |
|
| October 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 25, 2023 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of (Commission File Number) (I.R |
|
| October 25, 2023 |
CONMED Corporation Announces Third Quarter 2023 Financial Results NEWS RELEASE CONTACT: CONMED Corporation Todd W. Garner Chief Financial Officer 727-214-2975 [email protected] CONMED Corporation Announces Third Quarter 2023 Financial Results Largo, Florida, October 25, 2023 – CONMED Corporation (NYSE: CNMD) today announced financial results for the third quarter ended September 30, 2023. Third Quarter 2023 Highlights · Sales of $304.6 million increased 10.7 |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 10, 2023 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of (Commission File Number) (I.R. |
|
| July 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended Commission File Number June 30, 2023 001-39218 CONMED CORPORATION (Exact name of the registrant as spec |
|
| July 27, 2023 |
Amended and Restated Certificate of Incorporation of CONMED Corporation AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CONMED CORPORATION June 1, 2023 CONMED Corporation, a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), does hereby certify as follows: 1. |
|
| July 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 26, 2023 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of (Commission File Number) (I.R.S. |
|
| July 26, 2023 |
CONMED Corporation Announces Second Quarter 2023 Financial Results NEWS RELEASE CONTACT: CONMED Corporation Todd W. Garner Chief Financial Officer 727-214-2975 [email protected] CONMED Corporation Announces Second Quarter 2023 Financial Results Largo, Florida, July 26, 2023 – CONMED Corporation (NYSE: CNMD) today announced financial results for the second quarter ended June 30, 2023. Second Quarter 2023 Highlights · Sales of $317.7 million increased 14.6% yea |
|
| June 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 11-K ý Annual Report Pursuant To Section 15(d) Of The Securities Exchange Act of 1934 For the fiscal year ended December 31, 2022 OR ¨ Transition Report Pursuant To Section 15(d) Of The Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-39218 (A) Full title of the plan and the add |
|
| May 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2023 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| May 23, 2023 |
Conflict Minerals Report as responsive to Item 1.01 and 1.02 of this Form. Exhibit 1.01 CONMED Corporation Conflict Minerals Report For the Year Ended December 31, 2022 We have made statements in this Conflict Minerals Report that may constitute forward-looking statements about our plans to take additional actions or to implement additional procedures with respect to our due diligence efforts to determine the origin of conflict minerals included in our products. There ca |
|
| May 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of (Commission (I.R.S. Employer incorporation or organization) File Number) Identification No.) 11311 Concept Blvd. Largo FL 33773-4908 (Address of principal |
|
| April 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended Commission File Number March 31, 2023 001-39218 CONMED CORPORATION (Exact name of the registrant as spe |
|
| April 26, 2023 |
CONMED Corporation Announces First Quarter 2023 Financial Results NEWS RELEASE CONTACT: CONMED Corporation Todd W. Garner Chief Financial Officer 727-214-2975 [email protected] CONMED Corporation Announces First Quarter 2023 Financial Results Largo, Florida, April 26, 2023 – CONMED Corporation (NYSE: CNMD) today announced financial results for the first quarter ended March 31, 2023. First Quarter 2023 Highlights · Sales of $295.5 million increased 21.9% year |
|
| April 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 26, 2023 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of (Commission File Number) (I.R.S |
|
| April 11, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi |
|
| April 11, 2023 |
2022 ANNUAL REPORT ANNUAL REPORT 2022Contents Introduction Company Financial Snapshot Letter to Shareholders Featured Spotlights Board Members and Officers Additional Information GAAP to Non-GAAP Reconciliations CONMED 10-K 4 5 6 8 10 12 14 16 2022 ANNUAL REPORT4 | Introduction Future for the 2022 was the year for us to level up. |
|
| April 11, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi |
|
| March 30, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☑ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi |
|
| February 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 27, 2023 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of (Commission File Number) (I. |
|
| February 21, 2023 |
Description of the Common Stock of CONMED Corporation, a Delaware corporation. Exhibit 4.1 Description of Common Stock The following is a description of the general terms, provisions and rights of the common stock, par value $0.01 ("Common Stock"), of CONMED Corporation, a Delaware corporation (the "Company," "we," "us," and "our"), related provisions of the Company’s certificate of incorporation (the “Certificate of Incorporation”) and bylaws (the “Bylaws”) and applicable D |
|
| February 21, 2023 |
Subsidiaries of the Registrant. EXHIBIT 21 CONMED Corporation Subsidiaries of the Registrant Name State or Country of Incorporation Aspen Laboratories, Inc. |
|
| February 21, 2023 |
United States Securities and Exchange Commission Washington, D.C. 20549 Form 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended: December 31, 2022 Commission file number: 001-39218 CONMED CORPORATION (Exact name of registrant as specified |
|
| February 13, 2023 |
CNMD / Conmed Corp / EARNEST PARTNERS LLC - CONMED CORPORATION - 12/31/2022 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.4) CONMED CORPORATION - (Name of Issuer) Common Stock - (Title of Class of Securities) 207410101 - (CUSIP Number) 12/31/2022 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sched |
|
| February 13, 2023 |
SC 13G/A 1 CNMD123122.txt CHAMPLAIN 13G TICKER CNMD UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* CONMED Corporation (Name of Issuer) COMMON STOCK (Title of Class of Securities) 207410101 (CUSIP Number) 12/31/2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to de |
|
| February 13, 2023 |
CNMD / Conmed Corp / Capital Research Global Investors - SEC SCHEDULE 13G Passive Investment SC 13G 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* CONMED Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 207410101 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate |
|
| February 9, 2023 |
CNMD / Conmed Corp / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0647-conmedcorp.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 12)* Name of issuer: CONMED Corp. Title of Class of Securities: Common Stock CUSIP Number: 207410101 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule p |
|
| February 2, 2023 |
CONMED Corporation Announces Fourth Quarter and Full-Year 2022 Financial Results NEWS RELEASE CONTACT: CONMED Corporation Todd W. Garner Chief Financial Officer 727-214-2975 [email protected] CONMED Corporation Announces Fourth Quarter and Full-Year 2022 Financial Results Largo, Florida, February 2, 2023 – CONMED Corporation (NYSE: CNMD) today announced financial results for the fourth quarter and full-year ended December 31, 2022. Fourth Quarter 2022 Highlights · Fourth q |
|
| February 2, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 2, 2023 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of (Commission File Number) (I.R |
|
| January 26, 2023 |
CNMD / Conmed Corp / BlackRock Inc. Passive Investment SC 13G/A 1 us2074101013012623.txt us2074101013012623.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 18) CONMED CORPORATION - (Name of Issuer) Common Stock - (Title of Class of Securities) 207410101 - (CUSIP Number) December 31, 2022 - (Date of Event Which Requires Filing of this Statement) Check the appropriate bo |
|
| January 20, 2023 |
CNMD / Conmed Corp / BlackRock Inc. Passive Investment us2074101013012023.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 17) CONMED CORPORATION - (Name of Issuer) Common Stock - (Title of Class of Securities) 207410101 - (CUSIP Number) December 31, 2022 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant t |
|
| December 27, 2022 |
EX-10.1 2 d444290dex101.htm EX-10.1 Exhibit 10.1 THIRD AMENDMENT THIRD AMENDMENT, dated as of December 20, 2022 (this “Amendment”), to the Seventh Amended and Restated Credit Agreement, dated as of July 16, 2021 (as amended, supplemented or otherwise modified from time to time, the “Credit Agreement”), among CONMED Corporation, a Delaware corporation (the “Parent Borrower”), the Foreign Subsidiary |
|
| December 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2022 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of incorporation) (Commission Fi |
|
| December 7, 2022 |
Letter Agreement, by and between CONMED Corporation and Daniel S. Jonas, dated December 6, 2022. EX-10.1 Exhibit 10.1 Heather Cohen EVP Human Resources 11311 Concept Blvd Largo, FL 33773 December 6, 2022 Daniel S. Jonas, Esq. 1901 Walnut Street, Apartment 12B Rittenhouse Plaza Philadelphia, PA 19103 Re: Employment Transition and Retirement Agreement Dear Dan, This letter confirms our recent discussions regarding your continued at-will employment with CONMED Corporation (the “Company”), includ |
|
| December 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2022 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of incorporation) (Commission Fil |
|
| December 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 5, 2022 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of (Commission File Number) (I.R |
|
| November 15, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2022 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of incorporation) (Commission Fi |
|
| November 15, 2022 |
Exhibit 99.1 NEWS RELEASE CONTACT: CONMED Corporation Todd W. Garner Chief Financial Officer 727-214-2975 [email protected] CONMED Corporation Withdraws 2022 Financial Outlook due to Temporary Impact from Software Implementation; Provides 2023 Financial Outlook LARGO, Fla. ? November 15, 2022 ? CONMED Corporation (NYSE: CNMD) today announced that due to a temporary disruption resulting from th |
|
| November 15, 2022 |
Investor Presentation Curt R. Hartman Chair of the Board, President, and Chief Executive Officer Todd W. Garner Executive Vice President and Chief Financial Officer November 15, 2022 Exhibit 99.2 Forward-Looking Information This presentation contains forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties. The forward-looking statements are ma |
|
| October 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended Commission File Number September 30, 2022 001-39218 CONMED CORPORATION (Exact name of the registrant as |
|
| October 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 26, 2022 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of (Commission File Number) (I.R |
|
| October 26, 2022 |
CONMED Corporation Announces Third Quarter 2022 Financial Results NEWS RELEASE CONTACT: CONMED Corporation Todd W. Garner Chief Financial Officer 727-214-2975 [email protected] CONMED Corporation Announces Third Quarter 2022 Financial Results Largo, Florida, October 26, 2022 – CONMED Corporation (NYSE: CNMD) today announced financial results for the third quarter ended September 30, 2022. Third Quarter 2022 Highlights · Sales of $275.1 million increased 10.6 |
|
| August 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 11, 2022 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of (Commission File Number) (I.R. |
|
| August 9, 2022 |
CONMED Completes Acquisition of Biorez, Inc. Exhibit 99.1 NEWS RELEASE CONMED Corporation Todd Garner Chief Financial Officer 727-214-2975 [email protected] CONMED Completes Acquisition of Biorez, Inc. Largo, Florida, August 9, 2022 ? CONMED Corporation (NYSE: CNMD) today announced that it has completed its previously announced acquisition of privately-held Biorez, Inc. Biorez is a medical device start-up based in New Haven, CT and is fo |
|
| August 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2022 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other Jurisdiction of Incorporation) (Commission File |
|
| August 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2022 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other Jurisdiction of Incorporation) (Commission File |
|
| August 2, 2022 |
Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY ?[***]?, HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL. AGREEMENT AND PLAN OF MERGER by and among BIOREZ, INC., CONMED CORPORATION, PROMETHEUS MERGER SUB, INC. and SHAREHOLDER REPRESENTATIVE SERVICES LLC Dated as of August 1, |
|
| August 2, 2022 |
CONMED Announces Definitive Agreement to Acquire Biorez, Inc. Exhibit 99.1 NEWS RELEASE CONMED Corporation Todd Garner Chief Financial Officer 727-214-2975 [email protected] CONMED Announces Definitive Agreement to Acquire Biorez, Inc. ? Through this acquisition, CONMED acquires next generation bioinductive collagen scaffold technology for application in sports medicine soft tissue healing ? CONMED to host conference call today at 4:30 p.m. ET Largo, Flo |
|
| August 2, 2022 |
Exhibit 10.2 SECOND AMENDMENT SECOND AMENDMENT, dated as of August 1, 2022 (this ?Amendment?), to the Seventh Amended and Restated Credit Agreement, dated as of July 16, 2021 (as amended, supplemented or otherwise modified from time to time, the ?Credit Agreement?), among CONMED Corporation, a Delaware corporation (the ?Parent Borrower?), the Foreign Subsidiary Borrowers (as defined therein) from |
|
| July 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended Commission File Number June 30, 2022 001-39218 CONMED CORPORATION (Exact name of the registrant as spec |
|
| July 28, 2022 |
e 30, 2022, by and between CONMED Corporation and Exhibit 10.1 SUPPLEMENTAL INDENTURE 2.25% Convertible Senior Notes due 2027 SUPPLEMENTAL INDENTURE (this ?Supplemental Indenture?), dated as of June 30, 2022, between CONMED Corporation, a Delaware corporation, as issuer (the ?Company?), and U.S. Bank Trust Company, National Association, a national banking association organized under the laws of the United States of America, as trustee (the ?Trust |
|
| July 27, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 27, 2022 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of incorporation or organization) ( |
|
| July 27, 2022 |
CONMED Corporation Announces Second Quarter 2022 Financial Results Exhibit 99.1 NEWS RELEASE CONTACT: CONMED Corporation Todd W. Garner Chief Financial Officer 727-214-2975 [email protected] CONMED Corporation Announces Second Quarter 2022 Financial Results Largo, Florida, July 27, 2022 ? CONMED Corporation (NYSE: CNMD) today announced financial results for the second quarter ended June 30, 2022. Second Quarter 2022 Highlights ? Sales of $277.2 million increa |
|
| July 11, 2022 |
CNMD / Conmed Corp / EARNEST PARTNERS LLC - CONMED CORPORATION - 06/30/2022 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.3) CONMED CORPORATION - (Name of Issuer) Common Stock - (Title of Class of Securities) 207410101 - (CUSIP Number) 06/30/2022 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sched |
|
| June 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 11-K ? Annual Report Pursuant To Section 15(d) Of The Securities Exchange Act of 1934 For the fiscal year ended December 31, 2021 OR ? Transition Report Pursuant To Section 15(d) Of The Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-39218 (A) Full title of the plan and the add |
|
| June 13, 2022 |
CONMED Completes Acquisition of In2Bones Global, Inc. Exhibit 99.1 NEWS RELEASE CONMED Corporation Todd Garner Chief Financial Officer 727-214-2975 [email protected] CONMED Completes Acquisition of In2Bones Global, Inc. Largo, Florida, June 13, 2022 ? CONMED Corporation (NYSE: CNMD) today announced that it has completed its previously announced acquisition of privately-held In2Bones Global Inc. Headquartered in Memphis, Tennessee, In2Bones is a g |
|
| June 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2022 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other Jurisdiction of Incorporation) (Commission File N |
|
| June 7, 2022 |
Exhibit 10.13 Barclays Bank PLC 5 The North Colonnade Canary Wharf, London E14 4BB Facsimile: +44(20)77736461 Telephone: +44 (20) 777 36810 c/o Barclays Capital Inc. as Agent for Barclays Bank PLC 745 Seventh Avenue New York, NY 10019 Telephone: +1 212 412 4000 June 2, 2022 To: CONMED Corporation 11311 Concept Blvd Largo, Florida 33773 Attention: General Counsel Facsimile No.: 315-793-8928 Re: Add |
|
| June 7, 2022 |
Exhibit 10.16 JPMorgan Chase Bank, National Association New York Branch 383 Madison Avenue New York, NY 10179 June 2, 2022 To: CONMED Corporation 11311 Concept Blvd Largo, Florida 33773 Attention: General Counsel Facsimile No.: 315-793-8928 Re: Additional Call Option Transaction The purpose of this letter agreement (this ?Confirmation?) is to confirm the terms and conditions of the call option tra |
|
| June 7, 2022 |
Exhibit 10.7 Barclays Bank PLC 5 The North Colonnade Canary Wharf, London E14 4BB Facsimile: +44(20)77736461 Telephone: +44 (20) 777 36810 c/o Barclays Capital Inc. as Agent for Barclays Bank PLC 745 Seventh Avenue New York, NY 10019 Telephone: +1 212 412 4000 June 1, 2022 To: CONMED Corporation 11311 Concept Blvd Largo, Florida 33773 Attention: General Counsel Facsimile No.: 315-793-8928 Re: Base |
|
| June 7, 2022 |
Exhibit 10.3 Jefferies International Limited 100 Bishopsgate London EC2N 4JL United Kingdom c/o Jefferies LLC, as agent for Jefferies International Limited 520 Madison Avenue New York, NY 10022 Telephone: 212-284-2300 June 1, 2022 To: CONMED Corporation 11311 Concept Blvd Largo, Florida 33773 Attention: General Counsel Facsimile No.: 315-793-8928 Re: Base Call Option Transaction The purpose of thi |
|
| June 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2022 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| June 7, 2022 |
Exhibit 10.22 JPMorgan Chase Bank, National Association New York Branch 383 Madison Avenue New York, NY 10179 June 2, 2022 To: CONMED Corporation 11311 Concept Blvd Largo, Florida 33773 Attention: General Counsel Facsimile No.: 315-793-8928 Re: Additional Warrants The purpose of this letter agreement (this ?Confirmation?) is to confirm the terms and conditions of the Warrants issued by CONMED Corp |
|
| June 7, 2022 |
EX-10.8 11 d320648dex108.htm EX-10.8 Exhibit 10.8 Bank of America, N.A. One Bryant Park, 8th Fl. New York, NY 10036 Attention: Strategic Equity Solutions Group Telephone: 646-855-8900 Email: [email protected] June 1, 2022 To: CONMED Corporation 11311 Concept Blvd Largo, Florida 33773 Attention: General Counsel Facsimile No.: 315-793-8928 Re: Base Warrants The purpose of this let |
|
| June 7, 2022 |
Exhibit 10.2 Bank of America, N.A. One Bryant Park, 8th Fl. New York, NY 10036 Attention: Strategic Equity Solutions Group Telephone: 646-855-8900 Email: [email protected] June 1, 2022 To: CONMED Corporation 11311 Concept Blvd Largo, Florida 33773 Attention: General Counsel Facsimile No.: 315-793-8928 Re: Base Call Option Transaction The purpose of this letter agreement (this ?C |
|
| June 7, 2022 |
Exhibit 10.23 Nomura Global Financial Products Inc. c/o Nomura Securities International, Inc. Worldwide Plaza 309 West 49th Street New York, NY 10019 June 2, 2022 To: CONMED Corporation 11311 Concept Blvd Largo, Florida 33773 Attention: General Counsel Facsimile No.: 315-793-8928 Re: Additional Warrants The purpose of this letter agreement (this ?Confirmation?) is to confirm the terms and conditio |
|
| June 7, 2022 |
Exhibit 10.21 Jefferies International Limited 100 Bishopsgate London EC2N 4JL United Kingdom c/o Jefferies LLC, as agent for Jefferies International Limited 520 Madison Avenue New York, NY 10022 Telephone: 212-284-2300 June 2, 2022 To: CONMED Corporation 11311 Concept Blvd Largo, Florida 33773 Attention: General Counsel Facsimile No.: 315-793-8928 Re: Additional Warrants The purpose of this letter |
|
| June 7, 2022 |
Exhibit 10.4 JPMorgan Chase Bank, National Association New York Branch 383 Madison Avenue New York, NY 10179 June 1, 2022 To: CONMED Corporation 11311 Concept Blvd Largo, Florida 33773 Attention: General Counsel Facsimile No.: 315-793-8928 Re: Base Call Option Transaction The purpose of this letter agreement (this ?Confirmation?) is to confirm the terms and conditions of the call option transactio |
|
| June 7, 2022 |
Exhibit 10.6 June 1, 2022 To: CONMED Corporation 11311 Concept Blvd Largo, Florida 33773 Attention: General Counsel Facsimile No.: 315-793-8928 From: Wells Fargo Bank, National Association (?Dealer?) 30 Hudson Yards New York, NY 10001-2170 Email: [email protected] Re: Base Call Option Transaction The purpose of this letter agreement (this ?Confirmation?) is to confirm |
|
| June 7, 2022 |
Exhibit 10.9 Jefferies International Limited 100 Bishopsgate London EC2N 4JL United Kingdom c/o Jefferies LLC, as agent for Jefferies International Limited 520 Madison Avenue New York, NY 10022 Telephone: 212-284-2300 June 1, 2022 To: CONMED Corporation 11311 Concept Blvd Largo, Florida 33773 Attention: General Counsel Facsimile No.: 315-793-8928 Re: Base Warrants The purpose of this letter agreem |
|
| June 7, 2022 |
Exhibit 4.1 CONMED CORPORATION as Issuer AND U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION as Trustee INDENTURE Dated as of June 6, 2022 2.25% Convertible Senior Notes due 2027 TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS Section 1.01. Definitions 5 Section 1.02. References to Interest 18 ARTICLE 2 ISSUE, DESCRIPTION, EXECUTION, REGISTRATION AND EXCHANGE OF NOTES Section 2.01. Designation and Amou |
|
| June 7, 2022 |
Exhibit 10.12 June 1, 2022 To: CONMED Corporation 11311 Concept Blvd Largo, Florida 33773 Attention: General Counsel Facsimile No.: 315-793-8928 From: Wells Fargo Bank, National Association (?Dealer?) 30 Hudson Yards New York, NY 10001-2170 Email: [email protected] Re: Base Warrants The purpose of this letter agreement (this ?Confirmation?) is to confirm the terms and |
|
| June 7, 2022 |
Exhibit 4.2 SUPPLEMENTAL INDENTURE 2.625% Convertible Senior Notes due 2024 SUPPLEMENTAL INDENTURE (this ?Supplemental Indenture?), dated as of June 6, 2022, between CONMED Corporation, a Delaware corporation, as issuer (the ?Company?), and U.S. Bank Trust Company, National Association, as successor to MUFG Union Bank, N.A., a national banking association organized under the laws of the United Sta |
|
| June 7, 2022 |
Exhibit 10.11 Nomura Global Financial Products Inc. c/o Nomura Securities International, Inc. Worldwide Plaza 309 West 49th Street New York, NY 10019 June 1, 2022 To: CONMED Corporation 11311 Concept Blvd Largo, Florida 33773 Attention: General Counsel Facsimile No.: 315-793-8928 Re: Base Warrants The purpose of this letter agreement (this ?Confirmation?) is to confirm the terms and conditions of |
|
| June 7, 2022 |
Exhibit 10.17 Nomura Global Financial Products Inc. c/o Nomura Securities International, Inc. Worldwide Plaza 309 West 49th Street New York, NY 10019 June 2, 2022 To: CONMED Corporation 11311 Concept Blvd Largo, Florida 33773 Attention: General Counsel Facsimile No.: 315-793-8928 Re: Additional Call Option Transaction The purpose of this letter agreement (this ?Confirmation?) is to confirm the ter |
|
| June 7, 2022 |
Exhibit 10.5 Nomura Global Financial Products Inc. c/o Nomura Securities International, Inc. Worldwide Plaza 309 West 49th Street New York, NY 10019 June 1, 2022 To: CONMED Corporation 11311 Concept Blvd Largo, Florida 33773 Attention: General Counsel Facsimile No.: 315-793-8928 Re: Base Call Option Transaction The purpose of this letter agreement (this ?Confirmation?) is to confirm the terms and |
|
| June 7, 2022 |
EX-10.1 4 d320648dex101.htm EX-10.1 Exhibit 10.1 Barclays Bank PLC 5 The North Colonnade Canary Wharf, London E14 4BB Facsimile: +44(20)77736461 Telephone: +44 (20) 777 36810 c/o Barclays Capital Inc. as Agent for Barclays Bank PLC 745 Seventh Avenue New York, NY 10019 Telephone: +1 212 412 4000 June 1, 2022 To: CONMED Corporation 11311 Concept Blvd Largo, Florida 33773 Attention: General Counsel |
|
| June 7, 2022 |
Exhibit 10.10 JPMorgan Chase Bank, National Association New York Branch 383 Madison Avenue New York, NY 10179 June 1, 2022 To: CONMED Corporation 11311 Concept Blvd Largo, Florida 33773 Attention: General Counsel Facsimile No.: 315-793-8928 Re: Base Warrants The purpose of this letter agreement (this ?Confirmation?) is to confirm the terms and conditions of the Warrants issued by CONMED Corporatio |
|
| June 7, 2022 |
Exhibit 10.20 Bank of America, N.A. One Bryant Park, 8th Fl. New York, NY 10036 Attention: Strategic Equity Solutions Group Telephone: 646-855-8900 Email: [email protected] June 2, 2022 To: CONMED Corporation 11311 Concept Blvd Largo, Florida 33773 Attention: General Counsel Facsimile No.: 315-793-8928 Re: Additional Warrants The purpose of this letter agreement (this ?Confirmat |
|
| June 7, 2022 |
Exhibit 10.24 June 2, 2022 To: CONMED Corporation 11311 Concept Blvd Largo, Florida 33773 Attention: General Counsel Facsimile No.: 315-793-8928 From: Wells Fargo Bank, National Association (?Dealer?) 30 Hudson Yards New York, NY 10001-2170 Email: [email protected] Re: Additional Warrants The purpose of this letter agreement (this ?Confirmation?) is to confirm the ter |
|
| June 7, 2022 |
Exhibit 10.19 Barclays Bank PLC 5 The North Colonnade Canary Wharf, London E14 4BB Facsimile: +44(20)77736461 Telephone: +44 (20) 777 36810 c/o Barclays Capital Inc. as Agent for Barclays Bank PLC 745 Seventh Avenue New York, NY 10019 Telephone: +1 212 412 4000 June 2, 2022 To: CONMED Corporation 11311 Concept Blvd Largo, Florida 33773 Attention: General Counsel Facsimile No.: 315-793-8928 Re: Add |
|
| June 7, 2022 |
Exhibit 10.18 June 2, 2022 To: CONMED Corporation 11311 Concept Blvd Largo, Florida 33773 Attention: General Counsel Facsimile No.: 315-793-8928 From: Wells Fargo Bank, National Association (?Dealer?) 30 Hudson Yards New York, NY 10001-2170 Email: [email protected] Re: Additional Call Option Transaction The purpose of this letter agreement (this ?Confirmation?) is to |
|
| June 7, 2022 |
Exhibit 10.15 Jefferies International Limited 100 Bishopsgate London EC2N 4JL United Kingdom c/o Jefferies LLC, as agent for Jefferies International Limited 520 Madison Avenue New York, NY 10022 Telephone: 212-284-2300 June 2, 2022 To: CONMED Corporation 11311 Concept Blvd Largo, Florida 33773 Attention: General Counsel Facsimile No.: 315-793-8928 Re: Additional Call Option Transaction The purpose |
|
| June 7, 2022 |
Exhibit 10.25 FIRST AMENDMENT FIRST AMENDMENT, dated as of June 6, 2022 (this ?Amendment?), to the Seventh Amended and Restated Credit Agreement, dated as of July 16, 2021 (as amended, supplemented or otherwise modified from time to time, the ?Credit Agreement?), among CONMED Corporation, a Delaware corporation (the ?Parent Borrower?), the Foreign Subsidiary Borrowers (as defined therein) from tim |
|
| June 7, 2022 |
Exhibit 10.14 Bank of America, N.A. One Bryant Park, 8th Fl. New York, NY 10036 Attention: Strategic Equity Solutions Group Telephone: 646-855-8900 Email: [email protected] June 2, 2022 To: CONMED Corporation 11311 Concept Blvd Largo, Florida 33773 Attention: General Counsel Facsimile No.: 315-793-8928 Re: Additional Call Option Transaction The purpose of this letter agreement ( |
|
| June 2, 2022 |
CONMED Corporation Announces Pricing of Upsized $700 Million Offering of Convertible Senior Notes Exhibit 99.1 CONFIDENTIAL NEWS RELEASE CONTACT: CONMED Corporation Todd Garner Chief Financial Officer 727-241-2975 [email protected] CONMED Corporation Announces Pricing of Upsized $700 Million Offering of Convertible Senior Notes Largo, Florida, June 1, 2022 ? CONMED Corporation (NYSE: CNMD) today announced the pricing of $700 million aggregate principal amount of 2.25% convertible senior no |
|
| June 2, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2022 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| May 31, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 31, 2022 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| May 31, 2022 |
CONMED Corporation Announces Private Offering of $600 Million of Convertible Senior Notes EX-99.1 2 d355803dex991.htm EX-99.1 Exhibit 99.1 NEWS RELEASE CONTACT: CONMED Corporation Todd Garner Chief Financial Officer 727-214-2975 [email protected] CONMED Corporation Announces Private Offering of $600 Million of Convertible Senior Notes Largo, Florida, May 31, 2022 – CONMED Corporation (NYSE: CNMD) today announced that it intends to offer, subject to market conditions and other facto |
|
| May 26, 2022 |
Conflict Minerals Report as responsive to Item 1.01 and 1.02 of this Form. Exhibit 1.01 CONMED Corporation Conflict Minerals Report For the Year Ended December 31, 2021 We have made statements in this Conflict Minerals Report that may constitute forward-looking statements about our plans to take additional actions or to implement additional procedures with respect to our due diligence efforts to determine the origin of conflict minerals included in our products. There ca |
|
| May 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of (Commission (I.R.S. Employer incorporation or organization) File Number) Identification No.) 11311 Concept Blvd. Largo FL 33773-4908 (Address of principal |
|
| May 26, 2022 |
Other Events, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2022 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| May 5, 2022 |
EX-10.1 2 d664412dex101.htm EX-10.1 Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY “[***]”, HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL. AGREEMENT AND PLAN OF MERGER by and among IN2BONES GLOBAL, INC., CONMED CORPORATION, ODYSSEY MERGER SUB, INC. and SHERYL MOROSCHAK Da |
|
| May 5, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2022 (May 4, 2022) CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other Jurisdiction of Incorporation) (Commi |
|
| May 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended Commission File Number March 31, 2022 001-39218 CONMED CORPORATION (Exact name of the registrant as spe |
|
| May 4, 2022 |
CONMED Announces Definitive Agreement to Acquire In2Bones Global, Inc. EX-99.2 3 d351635dex992.htm EX-99.2 Exhibit 99.2 NEWS RELEASE CONMED Corporation Todd Garner Chief Financial Officer 727-214-2975 [email protected] CONMED Announces Definitive Agreement to Acquire In2Bones Global, Inc. Largo, Florida, May 4, 2022 – CONMED Corporation (NYSE: CNMD) today announced a definitive agreement to acquire privately-held In2Bones Global, Inc. (In2Bones), on a cash-free, |
|
| May 4, 2022 |
CONMED Corporation Announces First Quarter 2022 Financial Results Exhibit 99.1 NEWS RELEASE CONTACT: CONMED Corporation Todd W. Garner Chief Financial Officer 727-214-2975 [email protected] CONMED Corporation Announces First Quarter 2022 Financial Results Largo, Florida, May 4, 2022 ? CONMED Corporation (NYSE: CNMD) today announced financial results for the first quarter ended March 31, 2022. First Quarter 2022 Highlights ? Sales of $242.3 million increased |
|
| May 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2022 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other Jurisdiction of Incorporation) (Commission File Num |
|
| April 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| April 15, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defi |
|
| March 10, 2022 |
CNMD / Conmed Corp / EARNEST PARTNERS LLC - CONMED CORPORATION - 02/28/2022 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.2) CONMED CORPORATION - (Name of Issuer) Common Stock - (Title of Class of Securities) 207410101 - (CUSIP Number) 02/28/2022 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sched |
|
| March 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2022 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of incorporation) (Commission File N |
|
| March 7, 2022 |
Letter Agreement, by and between CONMED Corporation and Jed Kennedy, dated March 5, 2022. Exhibit 10.1 Heather Cohen EVP Human Resources 11311 Concept Blvd Largo, FL 33773 EXECUTION VERSION March 5, 2022 John (Jed) E. Kennedy 150 Belmont Avenue Lowell, MA 01852 Re: Group EVP, AET, QA/RA, Dist, CS Transition Dear Jed: This letter confirms our recent discussions regarding your continued employment as a Special Advisor of CONMED Corporation (the ?Company?) and your planned retirement. On |
|
| February 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 28, 2022 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of (Commission File Number) (I. |
|
| February 22, 2022 |
Description of the Common Stock of CONMED Corporation, a Delaware corporation. Exhibit 4.1 Description of Common Stock The following is a description of the general terms, provisions and rights of the common stock, par value $0.01 ("Common Stock"), of CONMED Corporation, a Delaware corporation (the "Company," "we," "us," and "our"), related provisions of the Company?s certificate of incorporation (the ?Certificate of Incorporation?) and bylaws (the ?Bylaws?) and applicable D |
|
| February 22, 2022 |
United States Securities and Exchange Commission Washington, D.C. 20549 Form 10-K ? Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 or ? Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended: December 31, 2021 Commission file number: 001-39218 CONMED CORPORATION (Exact name of registrant as specified |
|
| February 22, 2022 |
Subsidiaries of the Registrant. EXHIBIT 21 CONMED Corporation Subsidiaries of the Registrant Name State or Country of Incorporation Aspen Laboratories, Inc. |
|
| February 14, 2022 |
CNMD / Conmed Corp / EARNEST PARTNERS LLC - CONMED CORPORATION - 12/31/2021 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.1) CONMED CORPORATION - (Name of Issuer) Common Stock - (Title of Class of Securities) 207410101 - (CUSIP Number) 12/31/2021 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sched |
|
| February 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* CONMED Corporation (Name of Issuer) COMMON STOCK (Title of Class of Securities) 207410101 (CUSIP Number) 12/31/2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| February 9, 2022 |
CNMD / Conmed Corp / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 11)* Name of issuer: CONMED Corp. Title of Class of Securities: Common Stock CUSIP Number: 207410101 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule |
|
| January 27, 2022 |
CNMD / Conmed Corp / BlackRock Inc. Passive Investment us2074101013012722.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 16) CONMED CORPORATION - (Name of Issuer) Common Stock - (Title of Class of Securities) 207410101 - (CUSIP Number) December 31, 2021 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant t |
|
| January 26, 2022 |
CONMED Corporation Announces Fourth Quarter and Full-Year 2021 Financial Results EX-99.1 2 ex99-1.htm EX-99.1 NEWS RELEASE CONTACT: CONMED Corporation Todd W. Garner Chief Financial Officer 727-214-2975 [email protected] CONMED Corporation Announces Fourth Quarter and Full-Year 2021 Financial Results Largo, Florida, January 26, 2022 – CONMED Corporation (NYSE: CNMD) today announced financial results for the fourth quarter and full year ended December 31, 2021. Fourth Quart |
|
| January 26, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 26, 2022 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of (Commission File Number) (I.R |
|
| January 25, 2022 |
CNMD / Conmed Corp / BlackRock Inc. Passive Investment us2074101013012522.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 15) CONMED CORPORATION - (Name of Issuer) Common Stock - (Title of Class of Securities) 207410101 - (CUSIP Number) December 31, 2021 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant t |
|
| November 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 29, 2021 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of (Commission File Number) (I. |
|
| October 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended Commission File Number September 30, 2021 001-39218 CONMED CORPORATION (Exact name of the registrant as |
|
| October 27, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 27, 2021 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of (Commission File Number) (I.R |
|
| October 27, 2021 |
CONMED Corporation Announces Third Quarter Financial Results NEWS RELEASE CONTACT: CONMED Corporation Todd W. Garner Chief Financial Officer 727-214-2975 [email protected] CONMED Corporation Announces Third Quarter Financial Results Largo, Florida, October 27, 2021 ? CONMED Corporation (NYSE: CNMD) today announced financial results for the third quarter ended September 30, 2021. Third Quarter 2021 Highlights ? Sales of $248.8 million increased 4.6% year |
|
| August 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 12, 2021 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of (Commission File Number) (I.R. |
|
| July 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended Commission File Number June 30, 2021 001-39218 CONMED CORPORATION (Exact name of the registrant as spec |
|
| July 28, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 28, 2021 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of (Commission File Number) (I.R.S. |
|
| July 28, 2021 |
CONMED Corporation Announces Second Quarter Financial Results NEWS RELEASE CONTACT: CONMED Corporation Todd W. Garner Chief Financial Officer 727-214-2975 [email protected] CONMED Corporation Announces Second Quarter Financial Results Largo, Florida, July 28, 2021 ? CONMED Corporation (NYSE: CNMD) today announced financial results for the second quarter ended June 30, 2021. Second Quarter 2021 Highlights ? Sales of $255.2 million increased 61.7% year ove |
|
| July 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 16, 2021 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of incorporation) (Commission File N |
|
| July 16, 2021 |
Exhibit 10.2 FIFTH AMENDMENT TO GUARANTEE AND COLLATERAL AGREEMENT FIFTH AMENDMENT, dated as of July 16, 2021 (this ?Amendment?), to the Guarantee and Collateral Agreement, dated as of August 28, 2002 (as amended, modified or supplemented from time to time, the ?Guarantee and Collateral Agreement?), made by each of the signatories thereto (together with any other entity that may become a party the |
|
| July 16, 2021 |
Exhibit 10.1 SEVENTH AMENDED AND RESTATED CREDIT AGREEMENT among CONMED CORPORATION, as Parent Borrower, The Foreign Subsidiary Borrowers From Time to Time Parties Hereto, The Several Lenders from Time to Time Parties Hereto, and JPMORGAN CHASE BANK, N.A., as Administrative Agent Dated as of July 16, 2021 JPMORGAN CHASE BANK, N.A., BOFA SECURITIES INC., and WELLS FARGO SECURITIES, LLC, as Joint Le |
|
| June 18, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 11-K ? Annual Report Pursuant To Section 15(d) Of The Securities Exchange Act of 1934 For the fiscal year ended December 31, 2020 OR ? Transition Report Pursuant To Section 15(d) Of The Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-39218 (A) Full title of the plan and the add |
|
| May 27, 2021 |
Conflict Minerals Report as responsive to Item 1.01 and 1.02 of this Form. Exhibit 1.01 CONMED Corporation Conflict Minerals Report For the Year Ended December 31, 2020 We have made statements in this Conflict Minerals Report that may constitute forward-looking statements about our plans to take additional actions or to implement additional procedures with respect to our due diligence efforts to determine the origin of conflict minerals included in our products. There ca |
|
| May 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of (Commission (I.R.S. Employer incorporation or organization) File Number) Identification No.) 11311 Concept Blvd. Largo FL 33773-4908 (Address of principal |
